GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Buildings And Improvements

ANRO (Alto Neuroscience) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Buildings And Improvements?


Alto Neuroscience Buildings And Improvements Historical Data

The historical data trend for Alto Neuroscience's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Buildings And Improvements Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
- - - -

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Alto Neuroscience Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Alto Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience Headlines

From GuruFocus

FMR LLC Acquires Shares in Alto Neuroscience Inc

By GuruFocus News 11-13-2024